A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma [clinicaltrials:NCT01270464]

Bio2RDF uri

A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma [clinicaltrials:NCT01270464]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT01270464

Bio2RDF identifier

NCT01270464

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01270464

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01270464

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

315

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT01270464 arm group 6332b934d93bc852b220aae08a1279d6 [clinicaltrials_resource:NCT01270464/arm-group/6332b934d93bc852b220aae08a1279d6]

NCT01270464 arm group 6f8ce038bc50a5372fcaf86e4b300bb6 [clinicaltrials_resource:NCT01270464/arm-group/6f8ce038bc50a5372fcaf86e4b300bb6]

NCT01270464 arm group c81fd84af84034d01dd491cc4261d38c [clinicaltrials_resource:NCT01270464/arm-group/c81fd84af84034d01dd491cc4261d38c]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

The primary objective o ...... nts with eosinophilic asthma.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

A Study to Evaluate the Effica ...... Age) With Eosinophilic Asthma

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Overall change from baseline as assessed by Forced Expiratory Volume in 1 second (FEV1) baseline to week 16 [clinicaltrials_resource:d2ef2cb4b36323819868392c03ed1230]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Overall change from baseline as assessed by Forced Expiratory Volume in 1 second (FEV1) baseline to week 16 [clinicaltrials_resource:13c7d41c5af8cd4d797fbd1d0c739928]

Overall change from baseline as assessed by Forced Expiratory Volume in 1 second (FEV1) baseline to week 16 [clinicaltrials_resource:325f0db7ccfe34efc48c511556ecc227]

Overall change from baseline as assessed by Forced Expiratory Volume in 1 second (FEV1) baseline to week 16 [clinicaltrials_resource:681383192ef7676f57cae226ea716d90]

Overall change from baseline as assessed by Forced Expiratory Volume in 1 second (FEV1) baseline to week 16 [clinicaltrials_resource:6df52ea8323970975ec99f75eb5690c2]

Overall change from baseline as assessed by Forced Expiratory Volume in 1 second (FEV1) baseline to week 16 [clinicaltrials_resource:6e36a0933fbce816564d28e75c378d55]

Overall change from baseline as assessed by Forced Expiratory Volume in 1 second (FEV1) baseline to week 16 [clinicaltrials_resource:95738f9db7c71523a5c164a7ad6c9871]

Overall change from baseline as assessed by Forced Expiratory Volume in 1 second (FEV1) baseline to week 16 [clinicaltrials_resource:a036c1824e4e5925b337a1fa41f51600]

Overall change from baseline as assessed by Forced Expiratory Volume in 1 second (FEV1) baseline to week 16 [clinicaltrials_resource:b78356ab87cbc5c14881df0be0c48e13]

Overall change from baseline as assessed by Forced Expiratory Volume in 1 second (FEV1) baseline to week 16 [clinicaltrials_resource:dd9331b615998f5d71388b826197da5e]

completion date [clinicaltrials_vocabulary:completion-date]

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01270464 [clinicaltrials_resource:381bf7473c05e15b74f73afacb768d1b]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2010-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Reslizumab [clinicaltrials_resource:71138f28dab071af66eac9b79d247914]

Placebo [clinicaltrials_resource:f16403d21516ad301a9cfb8753cc8e8b]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2014-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Cephalon [clinicaltrials_resource:395eeae37599a2c044fede4d781aa919]

location [clinicaltrials_vocabulary:location]

Teva Investigational Site 12 [clinicaltrials_resource:6e2eafeab02efac954ddc6d03c5bba76]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01270464

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A 16-Week, Randomized, Double- ...... Age) With Eosinophilic Asthma

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

C38072/3081

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Sponsor's Medical Expert, Senior Director - Worldwide Clinical Research, MD [clinicaltrials_resource:289a9ae4f2161e6b709fa49062a371d9]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:f5d85ed026899b17c4d7ca50ffb5012c]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

2010-023342-67

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Teva Pharmaceutical Industries [clinicaltrials_resource:4a89e46ba43af85a198c0c303d967957]

start date [clinicaltrials_vocabulary:start-date]

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01270464 study design [clinicaltrials_resource:69635ae299e75dee20f4800ed5ea4a11]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01270464

verification date [clinicaltrials_vocabulary:verification-date]

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01270464

http://www.w3.org/2001/XMLSchema#string

title

A Study to Evaluate the Effica ...... Age) With Eosinophilic Asthma

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

A Study to Evaluate the Effica ...... a [clinicaltrials:NCT01270464]

@en